ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer

• Published in: Genes & development Vol. 35; no. 3-4; pp. 218 - 233
• Main Authors: Purohit, Vinee, Wang, Lidong, Yang, Huibin, Li, Jiufeng, Ney, Gina M, Gumkowski, Erica R, Vaidya, Akash J, Wang, Annie, Bhardwaj, Amit, Zhao, Ende, Dolgalev, Igor, Zamperone, Andrea, Abel, Ethan V, Magliano, Marina Pasca Di, Crawford, Howard C, Diolaiti, Daniel, Papagiannakopoulos, Thales Y, Lyssiotis, Costas A, Simeone, Diane M
• Format: Journal Article
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 01-02-2021
• Subjects: Carcinogenesis - genetics; DNA-Binding Proteins - metabolism; Drug Resistance, Neoplasm - genetics; Humans; Kelch-Like ECH-Associated Protein 1 - metabolism; NF-E2-Related Factor 2 - metabolism; Pancreatic Neoplasms; Pancreatic Neoplasms - physiopathology; Protein Binding; Research Paper; Transcription Factors - metabolism; tumor growth and invasion; pancreatic cancer; chemotherapeutic resistance; ATDC (Trim29)
• ISSN: 0890-9369; 1549-5477
• DOI: 10.1101/gad.344184.120

Pancreatic ductal adenocarcinoma is a lethal disease characterized by late diagnosis, propensity for early metastasis and resistance to chemotherapy. Little is known about the mechanisms that drive innate therapeutic resistance in pancreatic cancer. The ataxia-telangiectasia group D-associated gene (ATDC) is overexpressed in pancreatic cancer and promotes tumor growth and metastasis. Our study reveals that increased ATDC levels protect cancer cells from reactive oxygen species (ROS) via stabilization of nuclear factor erythroid 2-related factor 2 (NRF2). Mechanistically, ATDC binds to Kelch-like ECH-associated protein 1 (KEAP1), the principal regulator of NRF2 degradation, and thereby prevents degradation of NRF2 resulting in activation of a NRF2-dependent transcriptional program, reduced intracellular ROS and enhanced chemoresistance. Our findings define a novel role of ATDC in regulating redox balance and chemotherapeutic resistance by modulating NRF2 activity.